Skip to main content
Amgen seeks FDA nod for osteoporosis therapy

A biologics license application was resubmitted to the FDA by Amgen for Evenity, or romosozumab, being developed to treat postmenopausal women with osteoporosis who are at high risk of fracture. The filing included results from late-stage studies ARCH and BRIDGE.

Full Story: